Date
mai 27, 2020

As a science-driven industry that aims to address some of the world’s biggest healthcare challenges, the biopharmaceutical industry is uniquely positioned to respond rapidly to COVID-19.

It has deep scientific knowledge gained from decades of experience working on developing solutions for combatting a range of infectious diseases such as MERS, SARS, Ebola and influenza, as well as experience working with health authorities and regulators to find a fast-tracked approach to bringing safe and effective medicines, vaccines and diagnostics to the market for patients.

The rapid spread of SARS-CoV-2 across the globe is a major public health threat for all, with profound health, social and economic impacts around the world.

More than ever, we need effective international cooperation to ensure that no-one is left behind in the race to tackle the spread of COVID-19. This cooperation requires coordinated, multi-stakeholder action that includes the private sector as a critical partner. IFPMA members are fully committed to bringing their unique expertise in research, development and manufacturing of diagnostics, medicines and vaccines to the table. IFPMA members are also committed to work in close collaboration with national regulatory agencies, academia and global health stakeholders to maintain access to existing medicines and vaccines for treatment and prevention of other conditions, while also continuing clinical research into new options and treatments for serious, life-threatening diseases. For further information, click here).

i-news-events